Agenus Inc.
Clinical trials sponsored by Agenus Inc., explained in plain language.
-
Last-Resort immunotherapy combo opens for patients with no other options
Disease control AVAILABLEThis program provides early access to two investigational immunotherapy drugs, botensilimab and balstilimab, for people with serious or life-threatening cancers such as colorectal, pancreatic, lung, liver, melanoma, sarcoma, ovarian, or prostate cancer. It is for patients who hav…
Sponsor: Agenus Inc. • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
Cancer patients who responded to balstilimab can now continue treatment through expanded access
Disease control AVAILABLEThis expanded access study offers balstilimab alone or combined with zalifrelimab to cancer patients who previously received these drugs in a clinical trial and saw benefit. The goal is to allow continued treatment for those who qualify. Participants must have completed the earli…
Sponsor: Agenus Inc. • Aim: Disease control
Last updated May 14, 2026 12:05 UTC